Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 18025
Country/Region: Malawi
Year: 2018
Main Partner: Lighthouse Trust
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $6,295,974 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $143,309
Care: TB/HIV (HVTB) $420,847
Care: Pediatric Care and Support (PDCS) $299,279
Sexual Prevention: Abstinence/Be Faithful (HVAB) $137,563
Testing: HIV Testing and Counseling (HVCT) $1,645,335
Sexual Prevention: Other Sexual Prevention (HVOP) $66,162
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $82,537
Treatment: Adult Treatment (HTXS) $3,057,768
Treatment: Pediatric Treatment (PDTX) $443,174
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 4,401
HTS_SELF 15-19, Female, Directly-Assisted 2019 354
HTS_SELF 15-19, Female, Unassisted 2019 62
HTS_SELF 15-19, Male, Directly-Assisted 2019 289
HTS_SELF 15-19, Male, Unassisted 2019 115
HTS_SELF 20-24, Female, Directly-Assisted 2019 449
HTS_SELF 20-24, Female, Unassisted 2019 78
HTS_SELF 20-24, Male, Directly-Assisted 2019 359
HTS_SELF 20-24, Male, Unassisted 2019 144
HTS_SELF 25-29, Female, Directly-Assisted 2019 90
HTS_SELF 25-29, Female, Unassisted 2019 78
HTS_SELF 25-29, Male, Directly-Assisted 2019 717
HTS_SELF 25-29, Male, Unassisted 2019 144
HTS_SELF 30-34, Female, Directly-Assisted 2019 39
HTS_SELF 30-34, Female, Unassisted 2019 38
HTS_SELF 30-34, Male, Directly-Assisted 2019 358
HTS_SELF 30-34, Male, Unassisted 2019 71
HTS_SELF 35-39, Female, Directly-Assisted 2019 39
HTS_SELF 35-39, Female, Unassisted 2019 38
HTS_SELF 35-39, Male, Directly-Assisted 2019 358
HTS_SELF 35-39, Male, Unassisted 2019 71
HTS_SELF 40-49, Female, Directly-Assisted 2019 25
HTS_SELF 40-49, Female, Unassisted 2019 22
HTS_SELF 40-49, Male, Directly-Assisted 2019 211
HTS_SELF 40-49, Male, Unassisted 2019 42
HTS_SELF 50+, Female, Directly-Assisted 2019 17
HTS_SELF 50+, Female, Unassisted 2019 15
HTS_SELF 50+, Male, Directly-Assisted 2019 145
HTS_SELF 50+, Male, Unassisted 2019 29
HTS_SELF Directly-Assisted 2019 3,451
HTS_SELF Unassisted 2019 950
HTS_TST <5, Unknown Sex, Negative 2019 1,127
HTS_TST 15-19, Female, Negative 2019 76
HTS_TST 15-19, Male, Negative 2019 278
HTS_TST 20-24, Female, Negative 2019 76
HTS_TST 20-24, Male, Negative 2019 278
HTS_TST 25-29, Female, Negative 2019 952
HTS_TST 25-29, Female, Negative 2019 13,270
HTS_TST 25-29, Female, Negative 2019 56
HTS_TST 25-29, Female, Negative 2019 55
HTS_TST 25-29, Female, Negative 2019 4,320
HTS_TST 25-29, Female, Negative 2019 275
HTS_TST 25-29, Female, Negative 2019 1,212
HTS_TST 25-29, Male, Negative 2019 1,620
HTS_TST 25-29, Male, Negative 2019 157
HTS_TST 25-29, Male, Negative 2019 93
HTS_TST 25-29, Male, Negative 2019 4,221
HTS_TST 25-29, Male, Negative 2019 1,600
HTS_TST 25-29, Male, Negative 2019 2,995
HTS_TST 30-34, Female, Negative 2019 1,097
HTS_TST 30-34, Female, Negative 2019 858
HTS_TST 30-34, Female, Negative 2019 6,257
HTS_TST 30-34, Female, Negative 2019 51
HTS_TST 30-34, Female, Negative 2019 49
HTS_TST 30-34, Female, Negative 2019 3,890
HTS_TST 30-34, Female, Negative 2019 250
HTS_TST 30-34, Male, Negative 2019 2,559
HTS_TST 30-34, Male, Negative 2019 1,388
HTS_TST 30-34, Male, Negative 2019 132
HTS_TST 30-34, Male, Negative 2019 79
HTS_TST 30-34, Male, Negative 2019 3,608
HTS_TST 30-34, Male, Negative 2019 1,368
HTS_TST 35-39, Female, Negative 2019 795
HTS_TST 35-39, Female, Negative 2019 624
HTS_TST 35-39, Female, Negative 2019 2,863
HTS_TST 35-39, Female, Negative 2019 35
HTS_TST 35-39, Female, Negative 2019 34
HTS_TST 35-39, Female, Negative 2019 2,827
HTS_TST 35-39, Female, Negative 2019 181
HTS_TST 35-39, Male, Negative 2019 2,191
HTS_TST 35-39, Male, Negative 2019 1,187
HTS_TST 35-39, Male, Negative 2019 112
HTS_TST 35-39, Male, Negative 2019 67
HTS_TST 35-39, Male, Negative 2019 3,084
HTS_TST 35-39, Male, Negative 2019 1,170
HTS_TST 40-49, Female, Negative 2019 446
HTS_TST 40-49, Female, Negative 2019 352
HTS_TST 40-49, Female, Negative 2019 11,795
HTS_TST 40-49, Female, Negative 2019 16
HTS_TST 40-49, Female, Negative 2019 41
HTS_TST 40-49, Female, Negative 2019 1,587
HTS_TST 40-49, Female, Negative 2019 101
HTS_TST 40-49, Male, Negative 2019 2,824
HTS_TST 40-49, Male, Negative 2019 1,529
HTS_TST 40-49, Male, Negative 2019 148
HTS_TST 40-49, Male, Negative 2019 87
HTS_TST 40-49, Male, Negative 2019 3,982
HTS_TST 40-49, Male, Negative 2019 1,513
HTS_TST 50+, Male, Negative 2019 23
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 229,158
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 2,396
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 4,034
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 8,781
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 17
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 162
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 31
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 30
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 959
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 1,345
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 959
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,345
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 4
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 297
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 135
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 1,078
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 234
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 227
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 2,612
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 4,516
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 2,612
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 4,516
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 38
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 543
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 6,576
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 1,429
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 1,392
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 1,973
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 4,004
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 1,973
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 4,004
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 30
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 303
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 8,013
HTS_TST Service Delivery Point (Facility) TB: <1, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 12
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 2
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 2
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 87
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 164
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 87
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 164
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 13
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 398
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 3,205
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 700
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 683
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 7,524
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 17,851
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 7,524
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 17,851
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 146
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 780
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 823
HTS_TST_POS <5, Unknown Sex, Positive 2019 31
HTS_TST_POS 15-19, Female, Positive 2019 12
HTS_TST_POS 15-19, Male, Positive 2019 6
HTS_TST_POS 20-24, Female, Positive 2019 12
HTS_TST_POS 20-24, Male, Positive 2019 6
HTS_TST_POS 25-29, Female, Positive 2019 37
HTS_TST_POS 25-29, Female, Positive 2019 238
HTS_TST_POS 25-29, Female, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 214
HTS_TST_POS 25-29, Female, Positive 2019 42
HTS_TST_POS 25-29, Female, Positive 2019 65
HTS_TST_POS 25-29, Male, Positive 2019 88
HTS_TST_POS 25-29, Male, Positive 2019 31
HTS_TST_POS 25-29, Male, Positive 2019 9
HTS_TST_POS 25-29, Male, Positive 2019 6
HTS_TST_POS 25-29, Male, Positive 2019 102
HTS_TST_POS 25-29, Male, Positive 2019 130
HTS_TST_POS 30-34, Female, Positive 2019 89
HTS_TST_POS 30-34, Female, Positive 2019 43
HTS_TST_POS 30-34, Female, Positive 2019 102
HTS_TST_POS 30-34, Female, Positive 2019 5
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Female, Positive 2019 262
HTS_TST_POS 30-34, Female, Positive 2019 55
HTS_TST_POS 30-34, Male, Positive 2019 215
HTS_TST_POS 30-34, Male, Positive 2019 94
HTS_TST_POS 30-34, Male, Positive 2019 22
HTS_TST_POS 30-34, Male, Positive 2019 16
HTS_TST_POS 30-34, Male, Positive 2019 243
HTS_TST_POS 30-34, Male, Positive 2019 317
HTS_TST_POS 35-39, Female, Positive 2019 72
HTS_TST_POS 35-39, Female, Positive 2019 42
HTS_TST_POS 35-39, Female, Positive 2019 31
HTS_TST_POS 35-39, Female, Positive 2019 5
HTS_TST_POS 35-39, Female, Positive 2019 3
HTS_TST_POS 35-39, Female, Positive 2019 246
HTS_TST_POS 35-39, Female, Positive 2019 46
HTS_TST_POS 35-39, Male, Positive 2019 224
HTS_TST_POS 35-39, Male, Positive 2019 98
HTS_TST_POS 35-39, Male, Positive 2019 25
HTS_TST_POS 35-39, Male, Positive 2019 17
HTS_TST_POS 35-39, Male, Positive 2019 260
HTS_TST_POS 35-39, Male, Positive 2019 333
HTS_TST_POS 40-49, Female, Positive 2019 106
HTS_TST_POS 40-49, Female, Positive 2019 64
HTS_TST_POS 40-49, Female, Positive 2019 163
HTS_TST_POS 40-49, Female, Positive 2019 7
HTS_TST_POS 40-49, Female, Positive 2019 6
HTS_TST_POS 40-49, Female, Positive 2019 320
HTS_TST_POS 40-49, Female, Positive 2019 67
HTS_TST_POS 40-49, Male, Positive 2019 431
HTS_TST_POS 40-49, Male, Positive 2019 180
HTS_TST_POS 40-49, Male, Positive 2019 57
HTS_TST_POS 40-49, Male, Positive 2019 34
HTS_TST_POS 40-49, Male, Positive 2019 489
HTS_TST_POS 40-49, Male, Positive 2019 638
HTS_TST_POS 50+, Male, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) ANC: 10-14, Positive 2019 39
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 72
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 156
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 159
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 187
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 159
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 187
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 71
HTS_TST_POS Service Delivery Point (Facility) Inpatient: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 168
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 134
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 168
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 134
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 51
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 130
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 28
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 27
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 91
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 78
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 91
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 78
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 124
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 61
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 427
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 375
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 427
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 375
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 57
KP_PREV By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 4,871
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 4,871
PMTCT_ART Already on ART at beginning of current pregnancy 2019 1,159
PMTCT_ART New on ART 2019 744
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 1,903
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 31,389
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 1,523
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 382
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 1,905
PMTCT_EID Sum of Infant Age disaggregates 2019 1,905
PMTCT_STAT 25-29, Female 2019 10,722
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 410
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 10,038
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 275
PMTCT_STAT 30-34, Female 2019 1,981
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 74
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 1,852
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 52
PMTCT_STAT 35-39, Female 2019 407
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 18
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 381
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 10
PMTCT_STAT 40-49, Female 2019 59
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 2
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 56
PMTCT_STAT By Age (Numerator): 10-14 2019 74
PMTCT_STAT By Age (Numerator): 15-19 2019 7,078
PMTCT_STAT By Age (Numerator): 20-24 2019 11,044
PMTCT_STAT By Age (Numerator): 50+ 2019 24
PMTCT_STAT By Number of known positives: 10-14 2019 4
PMTCT_STAT By Number of known positives: 15-19 2019 270
PMTCT_STAT By Number of known positives: 20-24 2019 424
PMTCT_STAT By Number of new negative: 10-14 2019 70
PMTCT_STAT By Number of new negative: 15-19 2019 6,625
PMTCT_STAT By Number of new negative: 20-24 2019 10,339
PMTCT_STAT By Number of new negative: 50+ 2019 23
PMTCT_STAT By Number of new positives: 10-14 2019 1
PMTCT_STAT By Number of new positives: 15-19 2019 181
PMTCT_STAT By Number of new positives: 20-24 2019 284
PMTCT_STAT Number of new ANC and L&D clients 2019 33,037
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 31,389
PMTCT_STAT_den 25-29, Female 2019 11,290
PMTCT_STAT_den 30-34, Female 2019 2,078
PMTCT_STAT_den 35-39, Female 2019 425
PMTCT_STAT_den 40-49, Female 2019 62
PMTCT_STAT_den By Age (Denominator): <15-19 2019 7,451
PMTCT_STAT_den By Age (Denominator): 10-14 2019 81
PMTCT_STAT_den By Age (Denominator): 20-24 2019 11,627
PMTCT_STAT_den By Age (Denominator): 50+ 2019 23
PrEP_NEW Female 15-19 2019 150
PrEP_NEW Female 20-24 2019 350
PrEP_NEW FSW 2019 500
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 500
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 68
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 485
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 67
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 760
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 1,383
TB_PREV By Age/Sex (Numerator): <15, Female 2019 986
TB_PREV By Age/Sex (Numerator): <15, Male 2019 986
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 6,903
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 10,848
TB_PREV IPT, Life-long ART, Already, Positive 2019 1,973
TB_PREV IPT, Life-long ART, New, Positive 2019 17,750
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 19,723
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 21,914
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 1,096
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 1,096
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 7,670
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 12,052
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 2,191
TB_PREV_den IPT, Life-long ART, New, Positive 2019 19,723
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 129
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 887
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 129
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 1,396
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 2,541
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 2,555
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 130
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 892
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 131
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 1,402
TX_CURR 25-29, Female, Positive 2019 5,201
TX_CURR 25-29, Male, Positive 2019 1,277
TX_CURR 30-34, Female, Positive 2019 8,250
TX_CURR 30-34, Male, Positive 2019 2,848
TX_CURR 35-39, Female, Positive 2019 9,646
TX_CURR 35-39, Male, Positive 2019 4,667
TX_CURR 40-49, Female, Positive 2019 12,824
TX_CURR 40-49, Male, Positive 2019 9,675
TX_CURR Age/Sex: <1 2019 350
TX_CURR Age/Sex: <1-9 2019 3,538
TX_CURR Age/Sex: 10-14 Female 2019 2,039
TX_CURR Age/Sex: 10-14 Male 2019 1,905
TX_CURR Age/Sex: 15-19 Female 2019 1,345
TX_CURR Age/Sex: 15-19 Male 2019 1,371
TX_CURR Age/Sex: 20-24 Female 2019 3,103
TX_CURR Age/Sex: 20-24 Male 2019 1,097
TX_CURR Age/Sex: 50+ Female 2019 7,132
TX_CURR Age/Sex: 50+ Male 2019 7,409
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 83,677
TX_CURR Sum of age/sex disaggregates 2019 2,716
TX_NEW 25-29, Female, Positive 2019 447
TX_NEW 25-29, Male, Positive 2019 351
TX_NEW 30-34, Female, Positive 2019 541
TX_NEW 30-34, Male, Positive 2019 837
TX_NEW 35-39, Female, Positive 2019 527
TX_NEW 35-39, Male, Positive 2019 881
TX_NEW 40-49, Female, Positive 2019 662
TX_NEW 40-49, Male, Positive 2019 1,682
TX_NEW Breastfeeding status 2019 429
TX_NEW By Age/Sex: <1 2019 131
TX_NEW By Age/Sex: 1-9 2019 349
TX_NEW By Age/Sex: 10-14 Female 2019 51
TX_NEW By Age/Sex: 10-14 Male 2019 49
TX_NEW By Age/Sex: 15-19 Female 2019 799
TX_NEW By Age/Sex: 15-19 Male 2019 734
TX_NEW By Age/Sex: 20-24 Female 2019 967
TX_NEW By Age/Sex: 20-24 Male 2019 733
TX_NEW By Age/Sex: 50+ Female 2019 15
TX_NEW By Age/Sex: 50+ Male 2019 196
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 9,952
TX_NEW Pregnancy status 2019 1,627
TX_NEW Sum of Age/Sex disaggregates 2019 3,544
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 51,383
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 1,780
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 253
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,709
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 252
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 29,221
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 514
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 17,140
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 514
TX_PVLS_den Denominator: Indication: Routine 2019 49,842
TX_PVLS_den Denominator: Indication: Targeted 2019 1,541
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 507
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 504
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 4,692
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 6,096
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 11,799
TX_RET Numerator by Status: Breastfeeding 2019 342
TX_RET Numerator by Status: Pregnant 2019 190
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 11,910
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 527
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 524
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 4,723
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 6,136
TX_RET_den Denominator by Status: Breastfeeding 2019 433
TX_RET_den Denominator by Status: Pregnant 2019 212
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 129,078
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 6,455
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 6,454
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 45,180
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 70,989
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 77,434
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 51,644
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 129,078
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 114,883
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 1,288
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 12,777
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 130
Cross Cutting Budget Categories and Known Amounts Total: $4,519,533
Key Populations: MSM and TG $144,303
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Training of health workers and community outreach workers
Collection and use of strategic information
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $25,468
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Monitoring and evaluation of SW programs
Motor Vehicles: Purchased $405,000
Human Resources for Health $3,944,762